Faculty profile

Steeve Provencher

ResearcherMédecineUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Steeve Provencher

Researcher

Médecine

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
47 publications in the last five years, latest in 2026.
Senior (last) author on 8 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (6 CIHR), most recently in 2025.
Supervisor on 1 trainee award (1 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

154

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Pulmonary Hypertension Pulmonary Arterial Hypertension Pulmonary Hypertension, Lung Disease Clinical Trial Dna Damage Parp1 Inhibition Bromodomain Epigenetic Eraser

Latest papers

Outcomes of transition from selexipag to parenteral prostacyclin analogues in patients with pulmonary arterial hypertension.
ERJ open research · 2026
Treatment adherence of acute intermediate-high risk and high-risk pulmonary embolism: A retrospective cohort study.
Thrombosis research · 2026
Redefining Regulatory Proof: The End of the Two-Trial Paradigm.
Fundamental & clinical pharmacology · 2026

All 154 publications

Latest funding

Airway microbiome as a novel therapeutic target for pulmonary hypertension
CIHR · 2025 · Supervisor
$140,000
The Impact of Chronobiology on Pulmonary Arterial Hypertension: Insights into the Core Clock Protein Rev-Erb
CIHR · 2025 · Principal investigator
$1,090,126
Targeting Integrin Signaling to Alleviate Remodeling in Pulmonary Arteries and the Right Ventricle in Pulmonary Hypertension
CIHR · 2024 · Co-investigator
$856,800

All 19 grants and awards

From the 150 most recent of 154 publications.

Outcomes of transition from selexipag to parenteral prostacyclin analogues in patients with pulmonary arterial hypertension.

AlEissa E, Kolkman L, Kapasi A, Peng D, Provencher S, Brunner N, Swiston J

ERJ open research2026

DOI: 10.1183/23120541.00131-2026 PMID: 42683143

Treatment adherence of acute intermediate-high risk and high-risk pulmonary embolism: A retrospective cohort study.

Bissonnette C, Wong MK, Simon M, Provencher S, Mai V

Thrombosis research2026

DOI: 10.1016/j.thromres.2026.109797 PMID: 42623989

Redefining Regulatory Proof: The End of the Two-Trial Paradigm.

Lega JC, Provencher S, Falissard B, Locher C, Roustit M, Gougeon A, Boussageon R, Chevret S

Fundamental & clinical pharmacology2026

DOI: 10.1111/fcp.70110 PMID: 42595334

Reliability of accelerated confirmatory trials during the COVID-19 pandemic: the consequences of low pretrial plausibility.

Gougeon A, Massy E, Michal C, Rabilloud M, Provencher S, Bourguignon L, Boussageon R, Grenet G, Lega JC

Journal of clinical epidemiology2026

DOI: 10.1016/j.jclinepi.2026.112465 PMID: 42600710

The erosion of proof in paradigm transitions: the rise of narrative rationality in health technology assessment.

Lega JC, Gougeon A, Michal C, Provencher S, Naudet F, Falissard B, Chevret S, Boussageon R

Journal of clinical epidemiology2026

DOI: 10.1016/j.jclinepi.2026.112458 PMID: 42580367

Impaired Lung BCAA Metabolism Promotes Ferroptosis and Resultant Pulmonary Arterial Hypertension-Associated Hepatopathy.

Blake MJ, Hong J, Brownstein A, Rhodes CJ, Swietlik EM, Blake JC, Moon RA, Hartweck LM, Mendelson JB, Prisco SZ, Markowski T, Higgins L, Murray K, Guerrero C, Breuils-Bonnet S, Provencher S, Pepke-Zaba J, Toshner M, Wilkins M, Bonnet S, Prins KW

JACC. Basic to translational science2026

DOI: 10.1016/j.jacbts.2026.101573 PMID: 42214135

Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy.

Blake MJ, Prins SE, Blake J, Hartweck LM, Mendelson JB, Provencher S, Breuils-Bonnet S, Bonnet S, Prins KW

The Journal of clinical investigation2026

DOI: 10.1172/jci201862 PMID: 42207844

Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.

Zhang Y, Bonnet S, Provencher S, Piao J, Haromy A, Liu Y, Zhao YY, Breuils-Bonnet S, Lemay SE, Bowles DE, Mendiola Pla M, Sutendra G, Michelakis ED

Circulation2026

DOI: 10.1161/circulationaha.125.078674 PMID: 41797703

Pulmonary Arterial Hypertension Induces a Metabolic and Inflammatory Hepatopathy.

Blake MJ, Prins SE, Blake JC, Hartweck LM, Mendelson JB, Provencher S, Breuils-Bonnet S, Bonnet S, Prins KW

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.03.16.712114 PMID: 41890129

Alternative Polyadenylation Signatures Distinguish Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension: Implications for RNA-Based Diagnostics and Therapeutics.

Subramaniam J, Jonnakuti V, Collum SD, Martineau S, Huang KL, Breuils-Bonnet S, Frump AL, Akkanti BH, Patel JA, Patel MK, Salas de Armas I, Lefebvre IN, Radovancevic R, Blanco E, Wagner EJ, Gregoric I, Nathan S, Kar B, Provencher S, Bonnet S, Potus F, Yalamanchili HK, Karmouty-Quintana H

British journal of biomedical science2026

DOI: 10.3389/bjbs.2026.15687 PMID: 41799857

Something wrong or missing on this profile? Suggest a correction

Steeve Provencher

Research

Latest papers

Latest funding

Outcomes of transition from selexipag to parenteral prostacyclin analogues in patients with pulmonary arterial hypertension.

Treatment adherence of acute intermediate-high risk and high-risk pulmonary embolism: A retrospective cohort study.

Redefining Regulatory Proof: The End of the Two-Trial Paradigm.

Reliability of accelerated confirmatory trials during the COVID-19 pandemic: the consequences of low pretrial plausibility.

The erosion of proof in paradigm transitions: the rise of narrative rationality in health technology assessment.

Impaired Lung BCAA Metabolism Promotes Ferroptosis and Resultant Pulmonary Arterial Hypertension-Associated Hepatopathy.

Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy.

Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension.

Pulmonary Arterial Hypertension Induces a Metabolic and Inflammatory Hepatopathy.

Alternative Polyadenylation Signatures Distinguish Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension: Implications for RNA-Based Diagnostics and Therapeutics.

Frequent collaborators

Olivier Boucherat

Roxane Paulin

Sébastien Bonnet

Francois Potus

Jason Weatherald

Gopinath Sutendra

Jason Weatherald

Lisa Mielniczuk

Philippe Joubert

Benjamin Hibbert

Jean Bourbeau

Nathan Hambly

Julie Hallet

Kimberly Dunham-Snary

Rob Beanlands

George Chandy

Eva Suarthana

Caroline Sirois

Yan Burelle

John Granton

Paul Poirier

Philippe Pibarot

Andras Kapus

Lynn Megeney

Robert deKemp

Samir Gupta

Andrea Gershon

Martin Rainer Kolb

Jane Batt

Joshua Wald